METHODS: Data were pooled from two 52-week placebo-controlled trials of IV RES 3mg/kg (Q4wks) in patients aged ≥12 years with inadequately controlled eosinophilic (≥400 cells/μL) asthma. Baseline characteristics assessed included age, sex, BMI, baseline medications, ACQ-6, FEV1, FVC, blood eosinophils, and age of asthma onset. Outcome measures were assessed at 52 weeks.
RESULTS: Patients (N=477) receiving RES achieved FEV1 changes of ≥430mL (highest quartile) to ≤-100mL (lowest quartile); ACQ-6 changes of ≥-2.00 to ≤-0.67 and AQLQ changes of ≥2.00 to ≤0.44. For FEV1 (highest vs lowest quartile), baseline characteristics that differed significantly were: proportion using OCS (22% vs 11%, p=0.0356), mean ACQ-6 (2.71 vs 2.39, p=0.0137), and mean blood EOS (858 vs 514 cells/µL, p=0.0008). For ACQ-6: baseline mean blood EOS (824 vs 551, p=0.0094) and mean age of asthma onset (30 vs 23 years, p=0.0044). For AQLQ: baseline mean ACQ-6 (3.08 vs 2.20, p<0.0001), mean blood EOS (829 vs 577, p=0.0183), and mean asthma age of onset (29 vs 23, p=0.0383).
CONCLUSIONS: Baseline blood EOS and ACQ-6 score consistently predicted patients in the highest quartile for lung function and PROs. OCS use predicted FEV1 response; later age of onset predicted PRO responses.